Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ignacio Bernabeu

Showing results (21-30 of 45) with videos related to

Pageof 5
Sort By:
Endocrine|October 20, 2021
Acromegaly disease activity according to ACRODAT®, a cross-sectional study in Spain: ACROVAL studyMónica Marazuela, Concepción Blanco, Ignacio Bernabeu, et al.
The Journal of Clinical Endocrinology and Metabolism|March 9, 2010
Pegvisomant-induced liver injury is related to the UGT1A1*28 polymorphism of Gilbert's syndromeIgnacio Bernabeu, Mónica Marazuela, Tomás Lucas, et al.
Pituitary|April 15, 2026
Long-term safety and efficacy of pegvisomant monotherapy for acromegaly: final data from the full ACROSTUDY cohortKevin C J Yuen, Greisa Vila, Ignacio Bernabeu, et al.
Endocrinologia, Diabetes Y Nutricion|December 19, 2025
Executive summary of the consensus document for the management of severe Cushing's syndrome: Consensus document of the Neuroendocrinology Focus Group of the Spanish Society of Endocrinology and Nutrition (SEEN)Marta Araujo-Castro, Rogelio García-Centeno, Javier Aller, et al.
Frontiers in Endocrinology|October 19, 2020
GFRα 1-2-3-4 co-receptors for RET Are co-expressed in Pituitary Stem Cells but Individually Retained in Some Adenopituitary CellsAlberto Pradilla Dieste, Miguel Chenlo, Sihara Perez-Romero, et al.
Endocrine|October 6, 2016
Long-term outcome of multimodal therapy for giant prolactinomasPaula Andujar-Plata, Rocio Villar-Taibo, Maria Dolores Ballesteros-Pomar, et al.
Clinical Endocrinology|December 15, 2015
Long-term treatment with pegvisomant for acromegaly: a 10-year experienceAna M Ramos-Leví, Ignacio Bernabeu, Cristina Álvarez-Escolá, et al.
European Journal of Endocrinology|November 12, 2014
Analysis of IGF(CA)19 and IGFBP3-202A/C gene polymorphisms in patients with acromegaly: association with clinical presentation and response to treatmentsAna M Ramos-Leví, Mónica Marazuela, Amalia Paniagua, et al.
The Journal of Clinical Endocrinology and Metabolism|October 24, 2009
The exon 3-deleted growth hormone receptor is associated with better response to pegvisomant therapy in acromegalyIgnacio Bernabeu, Cristina Alvarez-Escolá, Celsa Quinteiro, et al.
European Journal of Endocrinology|January 17, 2009
Long-term treatment of acromegalic patients resistant to somatostatin analogues with the GH receptor antagonist pegvisomant: its efficacy in relation to gender and previous radiotherapyMónica Marazuela, Tomás Lucas, Cristina Alvarez-Escolá, et al.
Pageof 5

Showing results (21-30 of 45) with videos related to

Sort By:
Pageof 5
Endocrine|October 20, 2021
Acromegaly disease activity according to ACRODAT®, a cross-sectional study in Spain: ACROVAL studyMónica Marazuela, Concepción Blanco, Ignacio Bernabeu, et al.
The Journal of Clinical Endocrinology and Metabolism|March 9, 2010
Pegvisomant-induced liver injury is related to the UGT1A1*28 polymorphism of Gilbert's syndromeIgnacio Bernabeu, Mónica Marazuela, Tomás Lucas, et al.
Pituitary|April 15, 2026
Long-term safety and efficacy of pegvisomant monotherapy for acromegaly: final data from the full ACROSTUDY cohortKevin C J Yuen, Greisa Vila, Ignacio Bernabeu, et al.
Endocrinologia, Diabetes Y Nutricion|December 19, 2025
Executive summary of the consensus document for the management of severe Cushing's syndrome: Consensus document of the Neuroendocrinology Focus Group of the Spanish Society of Endocrinology and Nutrition (SEEN)Marta Araujo-Castro, Rogelio García-Centeno, Javier Aller, et al.
Frontiers in Endocrinology|October 19, 2020
GFRα 1-2-3-4 co-receptors for RET Are co-expressed in Pituitary Stem Cells but Individually Retained in Some Adenopituitary CellsAlberto Pradilla Dieste, Miguel Chenlo, Sihara Perez-Romero, et al.
Endocrine|October 6, 2016
Long-term outcome of multimodal therapy for giant prolactinomasPaula Andujar-Plata, Rocio Villar-Taibo, Maria Dolores Ballesteros-Pomar, et al.
Clinical Endocrinology|December 15, 2015
Long-term treatment with pegvisomant for acromegaly: a 10-year experienceAna M Ramos-Leví, Ignacio Bernabeu, Cristina Álvarez-Escolá, et al.
European Journal of Endocrinology|November 12, 2014
Analysis of IGF(CA)19 and IGFBP3-202A/C gene polymorphisms in patients with acromegaly: association with clinical presentation and response to treatmentsAna M Ramos-Leví, Mónica Marazuela, Amalia Paniagua, et al.
The Journal of Clinical Endocrinology and Metabolism|October 24, 2009
The exon 3-deleted growth hormone receptor is associated with better response to pegvisomant therapy in acromegalyIgnacio Bernabeu, Cristina Alvarez-Escolá, Celsa Quinteiro, et al.
European Journal of Endocrinology|January 17, 2009
Long-term treatment of acromegalic patients resistant to somatostatin analogues with the GH receptor antagonist pegvisomant: its efficacy in relation to gender and previous radiotherapyMónica Marazuela, Tomás Lucas, Cristina Alvarez-Escolá, et al.
Pageof 5